Ambry Genetics has launched four targeted sequencing-based cancer panels: CancerNext, BreastNext, ColoNext, and OvaNext.

The CancerNext panel targets and sequences 23 genes that contribute to increased risk for breast, colon, ovarian, uterine, and other cancers. It excludes the BRCA1 and BRCA2 genes. The test sequences the coding regions of all 23 genes, plus at least 20 bases into the 5' and 3' ends of the introns. Gross deletions and duplications are analyzed for 19 of the genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.